| S2617 |
TAK-733 |
TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. Phase 1. |
Selective |
MEK1, IC50: 3.2 nM |
| S1008 |
Selumetinib (AZD6244) |
Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3. |
Selective |
MEK1, IC50: 14 nM |
| S1177 |
PD98059 |
PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. |
Selective |
MEK1, IC50: 2 μM |
| S2673 |
Trametinib (GSK1120212) |
Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. |
Pan |
MEK1, IC50: 0.92 nM |
| S1020 |
PD184352 (CI-1040) |
PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM, 100-fold more selective for MEK1/2 than MEK5. Phase 2. |
Pan |
MEK1, IC50: 17 nM |
| S1089 |
Refametinib (RDEA119, Bay 86-9766) |
Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively. |
Pan |
MEK1, IC50: 19 nM |
| S1102 |
U0126-EtOH |
U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. |
Pan |
MEK1, IC50: 0.07 μM |
| S1066 |
SL-327 |
SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/ 0.22 μM, no activity towards Erk1, MKK3, MKK4, c-JUN, PKC, PKA, or CamKII;capable of transport through the blood-brain barrier. |
Pan |
MEK1, IC50: 0.18 μM |